# Maine — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

For Maine, price increase % trigger is insulin-specific: manufacturers must report WAC per pricing unit for each category of insulin; implementing agency is Maine Health Data Organization; statute is S.P. 996, verified against its source on 2026-08-15.

- **State:** Maine _(our reading, not quoted from the source)_
- **Price increase % trigger:** insulin-specific: manufacturers must report WAC per pricing unit for each category of insulin _(verified: appears in the quote below)_
- **Implementing agency:** Maine Health Data Organization _(verified: appears in the quote below)_
- **Statute:** S.P. 996 _(verified: appears in the quote below)_

## What the source says

> S.P. 996 now requires manufacturers of insulin to notify the Maine Health Data Organization of the WAC per pricing unit for insulin produced by the manufacturer in each category of insulin.

## Source

- https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws

Last verified: 2026-08-15. Review by: 2027-02-11.
Part of [State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers](https://referencesource.org/drug-price-transparency-thresholds/).